Is there a serum proteome signature to predict mortality in severe COVID-19 patients?
Franziska Völlmy, View ORCID ProfileHenk van den Toorn, View ORCID ProfileRiccardo Zenezini Chiozzi, View ORCID ProfileOttavio Zucchetti, Alberto Papi, View ORCID ProfileCarlo Alberto Volta, Luisa Marracino, View ORCID ProfileFrancesco Vieceli Dalla Sega, Francesca Fortini, View ORCID ProfileGianluca Campo, View ORCID ProfileMarco Contoli, View ORCID ProfileSavino Spadaro, View ORCID ProfilePaola Rizzo, View ORCID ProfileAlbert J.R. Heck
doi: https://doi.org/10.1101/2021.03.13.21253510
Franziska Völlmy
1Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, University of Utrecht, Padualaan 8, 3584 CH, Utrecht, The Netherlands
2Netherlands Proteomics Center, Padualaan 8, 3584 CH, Utrecht, The Netherlands
Henk van den Toorn
1Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, University of Utrecht, Padualaan 8, 3584 CH, Utrecht, The Netherlands
2Netherlands Proteomics Center, Padualaan 8, 3584 CH, Utrecht, The Netherlands
Riccardo Zenezini Chiozzi
1Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, University of Utrecht, Padualaan 8, 3584 CH, Utrecht, The Netherlands
2Netherlands Proteomics Center, Padualaan 8, 3584 CH, Utrecht, The Netherlands
Ottavio Zucchetti
3Cardiology Unit, Azienda Ospedaliero-Universitaria di Ferrara, University of Ferrara, Ferrara, Italy
Alberto Papi
4Respiratory Section, Department of Translational Medicine, University of Ferrara, Ferrara, Italy and Respiratory Disease Unit, Azienda Ospedaliero-Universitaria di Ferrara, Italy
Carlo Alberto Volta
5Department of Translational Medicine University of Ferrara, Ferrara, Italy and Intensive Care Unit, Azienda Ospedaliero-Universitaria di Ferrara, Italy
Luisa Marracino
6Department of Translational Medicine and Laboratory for Technology of Advanced Therapies (LTTA), University of Ferrara, Italy
Francesco Vieceli Dalla Sega
7Maria Cecilia Hospital, GVM Care & Research, Cotignola, Italy
Francesca Fortini
7Maria Cecilia Hospital, GVM Care & Research, Cotignola, Italy
Gianluca Campo
3Cardiology Unit, Azienda Ospedaliero-Universitaria di Ferrara, University of Ferrara, Ferrara, Italy
7Maria Cecilia Hospital, GVM Care & Research, Cotignola, Italy
Marco Contoli
4Respiratory Section, Department of Translational Medicine, University of Ferrara, Ferrara, Italy and Respiratory Disease Unit, Azienda Ospedaliero-Universitaria di Ferrara, Italy
Savino Spadaro
5Department of Translational Medicine University of Ferrara, Ferrara, Italy and Intensive Care Unit, Azienda Ospedaliero-Universitaria di Ferrara, Italy
Paola Rizzo
6Department of Translational Medicine and Laboratory for Technology of Advanced Therapies (LTTA), University of Ferrara, Italy
7Maria Cecilia Hospital, GVM Care & Research, Cotignola, Italy
Albert J.R. Heck
1Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, University of Utrecht, Padualaan 8, 3584 CH, Utrecht, The Netherlands
2Netherlands Proteomics Center, Padualaan 8, 3584 CH, Utrecht, The Netherlands
![Loading Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif)
Data Availability
The mass spectrometric proteomics data have been deposited at the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD024707.
Posted March 13, 2021.
Is there a serum proteome signature to predict mortality in severe COVID-19 patients?
Franziska Völlmy, Henk van den Toorn, Riccardo Zenezini Chiozzi, Ottavio Zucchetti, Alberto Papi, Carlo Alberto Volta, Luisa Marracino, Francesco Vieceli Dalla Sega, Francesca Fortini, Gianluca Campo, Marco Contoli, Savino Spadaro, Paola Rizzo, Albert J.R. Heck
medRxiv 2021.03.13.21253510; doi: https://doi.org/10.1101/2021.03.13.21253510
Is there a serum proteome signature to predict mortality in severe COVID-19 patients?
Franziska Völlmy, Henk van den Toorn, Riccardo Zenezini Chiozzi, Ottavio Zucchetti, Alberto Papi, Carlo Alberto Volta, Luisa Marracino, Francesco Vieceli Dalla Sega, Francesca Fortini, Gianluca Campo, Marco Contoli, Savino Spadaro, Paola Rizzo, Albert J.R. Heck
medRxiv 2021.03.13.21253510; doi: https://doi.org/10.1101/2021.03.13.21253510
Subject Area
Subject Areas
- Addiction Medicine (337)
- Allergy and Immunology (664)
- Anesthesia (179)
- Cardiovascular Medicine (2607)
- Dermatology (220)
- Emergency Medicine (392)
- Epidemiology (12150)
- Forensic Medicine (10)
- Gastroenterology (752)
- Genetic and Genomic Medicine (4038)
- Geriatric Medicine (381)
- Health Economics (672)
- Health Informatics (2609)
- Health Policy (995)
- Hematology (359)
- HIV/AIDS (834)
- Medical Education (397)
- Medical Ethics (109)
- Nephrology (429)
- Neurology (3810)
- Nursing (208)
- Nutrition (567)
- Oncology (1996)
- Ophthalmology (580)
- Orthopedics (235)
- Otolaryngology (303)
- Pain Medicine (250)
- Palliative Medicine (73)
- Pathology (470)
- Pediatrics (1102)
- Primary Care Research (443)
- Public and Global Health (6478)
- Radiology and Imaging (1380)
- Respiratory Medicine (867)
- Rheumatology (396)
- Sports Medicine (337)
- Surgery (439)
- Toxicology (52)
- Transplantation (185)
- Urology (165)